Insmed Incorporated reported a 44 percent sequential increase in revenue for its oral drug Brinsupri during the first quarter of 2026.
The announcement came during the company's earnings call on May 13, 2026, as reported by Detik Finance.
The global biopharmaceutical company maintained its confidence in achieving a 2026 annual revenue outlook of at least $1 billion.
This target is supported by stable pricing strategies and steady patient acquisition trends.
Financial Adjustments and Analyst Response
Truist recently adjusted its financial model for Insmed following the first quarter results.
The firm lowered its price target on the shares to $185 from $205 while preserving a Buy rating.
President, CEO, and Chairman William Lewis stated that the impact from inventory stocking during the quarter remained minimal for Brinsupri.
Brinsupri is a once-daily oral reversible inhibitor of dipeptidyl peptidase 1.
Patient access and adherence metrics remained positive throughout the quarter.
Approval rates since the initial product launch have hovered close to 90 percent.
Company data indicated that nearly 7,800 new patients commenced treatment during the quarter.
Approximately 1,500 individuals originated from an initial backlog pool.
Management noted that the temporary revenue surge associated with this specific patient segment had largely concluded.
Operations have now transitioned into the second quarter of the fiscal year.
Furthermore, more than 80 percent of the total patient base utilizing the medication successfully enrolled in the corporate inLighten patient support program.
